| Literature DB >> 27543472 |
Maniyal Vijayakumar1, D M Vasudevan2, K R Sundaram3, Sajitha Krishnan2, Kannan Vaidyanathan4, Sandya Nandakumar5, Rajiv Chandrasekhar6, Navin Mathew6.
Abstract
BACKGROUND AND RATIONALE: Coronary artery disease (CAD) and its pathological atherosclerotic process are closely related to lipids. Lipids levels are in turn influenced by dietary oils and fats. Saturated fatty acids increase the risk for atherosclerosis by increasing the cholesterol level. This study was conducted to investigate the impact of cooking oil media (coconut oil and sunflower oil) on lipid profile, antioxidant mechanism, and endothelial function in patients with established CAD. DESIGN AND METHODS: In a single center randomized study in India, patients with stable CAD on standard medical care were assigned to receive coconut oil (Group I) or sunflower oil (Group II) as cooking media for 2 years. Anthropometric measurements, serum, lipids, Lipoprotein a, apo B/A-1 ratio, antioxidants, flow-mediated vasodilation, and cardiovascular events were assessed at 3 months, 6 months, 1 year, and 2 years.Entities:
Keywords: Atherosclerosis; Cholesterol; Coconut oil; Cooking medium; Sunflower oil
Mesh:
Substances:
Year: 2016 PMID: 27543472 PMCID: PMC4990731 DOI: 10.1016/j.ihj.2015.10.384
Source DB: PubMed Journal: Indian Heart J ISSN: 0019-4832
Fig. 1Randomization, allocation, follow-up, and analysis.
Baseline characteristics of patients.
| Parameter | Group I | Group II | |
|---|---|---|---|
| Age | 58.97 (SD – 8.44) | 58.97 (SD – 8.93) | 1 |
| Gender (%) | 93.9 (male) | 92.9 (male) | 1 |
| 6.1 (female) | 7.1 (female) | ||
| Hypertension (%) | 58.2 | 55.1 | 0.67 |
| Diabetes (%) | 53.1 | 60.2 | 0.31 |
| Dislipidemia (%) | 74.0 | 63.0 | 0.09 |
| Ex smoking (%) | 54.1 | 57.1 | 0.77 |
| Active lifestyle (%) | 96.9 | 87.8 | 0.29 |
| Asymptomatic cardiac status (%) | 93.9 | 93.9 | 0.24 |
| Positive stress test (%) | 18.4 | 15.3 | 0.7 |
| STEMI (%) | 49.0 | 49.0 | 1.0 |
| NSTE MI (%) | 11.2 | 9.2 | 0.81 |
| Occupation | |||
| Skilled (%) | 32.7 | 30.9 | 0.71 |
| Professional (%) | 13.3 | 17.5 | |
| Retired (%) | 54.1 | 51.5 | |
| Family history of CAD | |||
| In parents (%) | 24.5 | 17.3 | 0.3 |
| In siblings (%) | 8.2 | 14.3 | |
| In parents and siblings (%) | 18.4 | 14.3 | |
| Confirmation of CAD (%) | |||
| CAG | 53.1 | 53.1 | 0.49 |
| ECG | 2.0 | 1.0 | |
| Multi-modality | 44.9 | 45.9 | |
| Revascularization | |||
| PTCA | 61.6 | 56.2 | 0.13 |
| CABG | 20.4 | 22.4 | 0.86 |
Anthropometric measurements.
| Group I | Group II | ||||
|---|---|---|---|---|---|
| Visits | Mean | SD | Mean | SD | |
| Weight (kg) | |||||
| Baseline | 63.61 | 8.51 | 64.51 | 8.43 | 0.44 |
| 1 Year | 63.88 | 8.74 | 64.53 | 8.68 | 0.60 |
| 2 Years | 64.23 | 8.78 | 64.80 | 9.00 | 0.65 |
| BMI | |||||
| Baseline | 25.06 | 6.00 | 24.38 | 2.99 | 0.32 |
| 1 Year | 24.60 | 3.13 | 24.39 | 3.10 | 0.63 |
| 2 Years | 24.72 | 3.07 | 24.54 | 3.07 | 0.68 |
| Waist hip ratio | |||||
| Baseline | 0.95 | 0.05 | 0.95 | 0.07 | 0.89 |
| 1 Year | 0.95 | 0.04 | 0.97 | 0.05 | 0.06 |
| 2 Years | 0.97 | 0.05 | 0.96 | 0.05 | 0.37 |
| Percentage body fat | |||||
| Baseline | 18.15 | 4.05 | 18.59 | 4.32 | 0.46 |
| 1 Year | 18.48 | 3.81 | 18.39 | 4.64 | 0.88 |
| 2 Years | 17.48 | 2.91 | 17.39 | 3.62 | 0.77 |
Lipid profile.
| Group I | Group II | ||||
|---|---|---|---|---|---|
| Visits | Mean | SD | Mean | SD | |
| Total cholesterol, mg/100 ml | |||||
| Baseline | 149.81 | 29.92 | 146.79 | 26.55 | 0.45 |
| 3 Months | 151.19 | 30.15 | 143.43 | 30.22 | 0.07 |
| 1 Year | 144.58 | 30.92 | 139.80 | 33.75 | 0.30 |
| 2 Years | 149.28 | 28.57 | 151.63 | 44.54 | 0.66 |
| LDL, mg/100 ml | |||||
| Baseline | 90.29 | 24.38 | 86.10 | 19.62 | 0.18 |
| 3 Months | 89.31 | 24.75 | 84.12 | 22.16 | 0.12 |
| 1 Year | 91.02 | 20.66 | 87.56 | 25.31 | 0.29 |
| 2 Years | 91.04 | 21.82 | 89.62 | 28.91 | 0.70 |
| Triglycerides, mg/100 ml | |||||
| Baseline | 114.96 | 54.22 | 111.17 | 48.85 | 0.60 |
| 3 Months | 111.23 | 37.26 | 108.90 | 39.28 | 0.67 |
| 1 Year | 112.00 | 50.19 | 114.52 | 64.83 | 0.76 |
| 2 Years | 109.32 | 47.06 | 112.20 | 45.15 | 0.66 |
| HDL, mg/100 ml | |||||
| Baseline | 40.80 | 9.16 | 40.74 | 9.95 | 0.96 |
| 3 Months | 40.82 | 10.92 | 39.57 | 9.68 | 0.39 |
| 1 Year | 42.41 | 9.48 | 40.10 | 11.10 | 0.11 |
| 2 Years | 43.22 | 10.77 | 44.36 | 16.35 | 0.56 |
| VLDL, mg/100 ml | |||||
| Baseline | 21.82 | 8.00 | 23.27 | 16.76 | 0.44 |
| 3 Months | 22.31 | 7.43 | 21.61 | 7.74 | 0.52 |
| 1 Year | 21.27 | 9.58 | 22.43 | 15.41 | 0.44 |
| 2 Years | 21.77 | 9.37 | 22.53 | 9.72 | 0.58 |
| NEFA, nmol/L | |||||
| Baseline | 0.44 | 0.32 | 0.45 | 0.28 | 0.97 |
| 3 Months | 0.61 | 0.32 | 0.6 | 0.35 | 0.95 |
| 1 Year | 0.57 | 0.31 | 0.72 | 0.45 | 0.01 |
| 2 Years | 0.58 | 0.35 | 0.54 | 0.36 | 0.45 |
Carrier proteins.
| Group I | Group II | ||||
|---|---|---|---|---|---|
| Visits | Mean | SD | Mean | SD | |
| Lipoprotein a (Lpa), mg/100 ml | |||||
| Baseline | 21.81 | 21.89 | 25.13 | 28.73 | 0.28 |
| 1 Year | 24.63 | 25.08 | 28.91 | 33.33 | 0.31 |
| 2 Years | 22.46 | 20.24 | 30.64 | 31.13 | 0.03 |
| Apo B/A ratio | |||||
| Baseline | 0.538 | 0.234 | 0.545 | 0.284 | 0.850 |
| 1 Year | 0.585 | 0.236 | 0.577 | 0.303 | 0.840 |
| 2 Years | 0.635 | 0.394 | 0.640 | 0.380 | 0.925 |
Flow-mediated vasodilatation. Median of absolute increase and percentage increase.
| Variables | Group I | Group II | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Median | Minimum | Maximum | Median | Minimum | Maximum | ||||
| ABIN1 | 98 | 0.30 | 0.01 | 1.20 | 98 | 0.28 | 0.00 | 1.30 | 0.57 |
| PRIN1 | 98 | 7.02 | 0.24 | 27.27 | 98 | 7.07 | 0.00 | 34.21 | 0.58 |
| ABIN2 | 98 | 0.22 | 0.00 | 0.87 | 98 | 0.22 | 0.00 | 0.99 | 0.51 |
| PRIN2 | 98 | 5.70 | 0.00 | 25.40 | 98 | 5.47 | 0.00 | 30.84 | 0.49 |
| ABIN3 | 96 | 0.25 | 0.01 | 0.95 | 94 | 0.27 | 0.00 | 1.03 | 0.75 |
| PRIN3 | 96 | 6.82 | 0.24 | 29.69 | 94 | 6.85 | 0.00 | 30.30 | 0.72 |
ABIN – absolute increase, PRIN – percentage increase.
Antioxidants.
| Group I | Group II | ||||
|---|---|---|---|---|---|
| Visits | Mean | SD | Mean | SD | |
| Lipidperoxidase [nmol/ml] | |||||
| Baseline | 0.139 | 0.070 | 0.148 | 0.104 | 0.508 |
| 3 Months | 0.120 | 0.036 | 0.124 | 0.038 | 0.509 |
| 1 Year | 0.146 | 0.134 | 0.160 | 0.179 | 0.542 |
| 2 Years | 0.150 | 0.132 | 0.128 | 0.042 | 0.119 |
| Glutathione reductase [nmol NADPH oxidase/m/mg protein] | |||||
| Baseline | 0.0040 | 0.0020 | 0.00392 | 0.0018 | 0.553 |
| 3 Months | 0.0044 | 0.0021 | 0.00454 | 0.0017 | 0.617 |
| 1 Year | 0.0051 | 0.00195 | 0.0047 | 0.0017 | 0.199 |
| 2 Years | 0.0050 | 0.0016 | 0.0049 | 0.0016 | 0.731 |
| Glutathione S transferase [nmol CDNB coagulate formed/mg protein/min] | |||||
| Baseline | 0.0017 | 0.00165 | 0.0019 | 0.0025 | 0.522 |
| 3 Months | 0.00196 | 0.00105 | 0.00280 | 0.0015 | 0.540 |
| 1 Year | 0.00269 | 0.0026 | 0.0027 | 0.0020 | 0.987 |
| 2 Years | 0.00285 | 0.0011 | 0.0028 | 0.0014 | 0.852 |
| Superoxide dismutase [U/mg hemoglobin] | |||||
| Baseline | 2 | 0.77 | 2.02 | 0.75 | 0.813 |
| 3 Months | 2.07 | 0.75 | 2.10 | 0.81 | 0.756 |
| 1 Year | 1.79 | 0.88 | 2.13 | 1.28 | 0.037 |
| 2 Years | 1.64 | 0.61 | 1.80 | 0.61 | 0.072 |
| Catalase [mmol H2O2 decomposed/mg protein/min] | |||||
| Baseline | 0.02091 | 0.04283 | 0.01854 | 0.01854 | 0.617 |
| 3 Months | 0.01534 | 0.01426 | 0.02005 | 0.0259 | 0.117 |
| 1 year | 0.01217 | 0.01609 | 0.01402 | 0.01786 | 0.459 |
| 2 years | 0.00619 | 0.01201 | 0.00459 | 0.00700 | 0.267 |
Anti-inflammatory markers.
| Group I | Group II | ||||
|---|---|---|---|---|---|
| Visits | Mean | SD | Mean | SD | |
| Ultra sensitive C-reactive protein [IU/L] | |||||
| Baseline | 1.5732 | 1.9016 | 1.289 | 1.65 | 0.265 |
| 2 Years | 1.23 | 1.59 | 1.43 | 1.72 | 0.411 |
Glycemic control.
| Group I | Group II | ||||
|---|---|---|---|---|---|
| Visits | Mean | SD | Mean | SD | |
| HbAIc | |||||
| Baseline | 6.62 | 1.20 | 6.79 | 1.19 | 0.316 |
| 1 Year | 6.6 | 1.28 | 6.69 | 1.2 | 0.578 |
| 2 Years | 6.54 | 1.32 | 6.77 | 1.28 | 0.229 |
Cardiovascular events during 2 years.
| Group I | Group II | |
|---|---|---|
| Death | 2 | 0 |
| Myocardial infarction | 0 | 0 |
| Stroke | 0 | 0 |
| Repeat revascularization | 2 | 2 |
Statins and dosage.
| Statin dosage | Group I | Group II | |||||
|---|---|---|---|---|---|---|---|
| Median | Min–max | Median | Min–max | ||||
| Visit 1 | |||||||
| Atrovastatin | 68 | 20 | 5–40 | 63 | 20 | 5–40 | 0.448 |
| Simvastatin | 12 | 10 | 5–20 | 16 | 10 | 5–40 | 0.391 |
| Rosuvastatin | 16 | 10 | 5–20 | 18 | 10 | 5–20 | 0.552 |
| Visit 2 | |||||||
| Atrovastatin | 64 | 20 | 5–60 | 62 | 10 | 5–60 | 0.632 |
| Simvastatin | 11 | 15 | 5–20 | 13 | 20 | 10–40 | 0.288 |
| Rosuvastatin | 18 | 10 | 5–20 | 22 | 10 | 5–20 | 0.376 |
| Visit 3 | |||||||
| Atrovastatin | 62 | 20 | 5–80 | 59 | 10 | 5–40 | 0.221 |
| Simvastatin | 10 | 10 | 5–20 | 10 | 15 | 10–40 | 0.402 |
| Rosuvastatin | 21 | 10 | 5–30 | 24 | 10 | 5–25 | 0.916 |
Inclusion/exclusion criteria.
| No. | Section A: Inclusion criteria |
|---|---|
| 1 | Male/Female – 18 years of age or older |
| 2 | Clinical evidence of CAD with one of the following |
| (a) Significant CAD in at least one of the epicardial coronary arteries confirmed by angiography | |
| (b) Previous MI or Acute Coronary Syndrome (UA/NSTEMI) not <3-month duration | |
| (c) Objective evidence of myocardial ischemia (TMT, pharmacological stress test or radionuclide scan) with symptoms or on treatment | |
| (d) MDCT evidence of significant CAD | |
| (e) Pathological Q wave in ECG and or RWMA in Echo | |
| 3 | Have achieved target lipid Levels as per adult treatment panel III (ATP-III) guidelines and good glycemic control (HbA1c < 7 mg%) |
| 4 | Subjects willing to comply with all follow-up visits |
| 5 | Subjects signed and received copy of informed consent for trial |